- Circulation of EJOP 2012 is more than 3,000 ESOP members (increased by 57% since 2009 and still growing), with a market penetration in 34 countries
- France, Germany and the UK represent 74% of the total circulation
- EJOP is distributed at the annual ESOP Congress in January and at the major annual European oncology congress in September/October each year
Current Development of EJOP
EJOP was first published in 2007 as a communication platform for oncology pharmacists and pharmacy technicians. EJOP aims to provide regular updates to oncology pharmacy practitioners and technicians for their continuous learning and practice improvement and to upkeep their knowledge and skills in the healthcare setting.
Practitioners in the area of hospital and oncology pharmacy who would like to author papers on topics relating to their profession and the manuscripts comply with the editorial policy of EJOP or GaBI Journal are welcome to submit their manuscripts for assessment, peer review approval and publication in EJOP or GaBI Journal.
EJOP, published quarterly, sets out to offer a professional communication platform to European oncology and hospital pharmacy practitioners. As the official journal of the European Society of Oncology Pharmacy (ESOP), the scope of EJOP is to satisfy ESOP members’ needs in terms of improvement on professional standard, setting guidelines, further education and sharing practice experience. EJOP offers ESOP members an insight into the differences and commonalities of oncology pharmacy standards and training, as well as the opportunities to learn the unique benefits and advantages from the different oncology pharmacy practitioners.
Advertise in EJOP
EJOP offers a direct communication platform with European oncology and hospital pharmacists who are active players in oncology pharmacy.